A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan (WELIREG(TM)) in patients with advanced or metastatic renal cell carcinoma, NCT06234605 Meeting Abstract
| Authors: | McKay, R. R.; Garmezy, B.; Barata, P.; Ornstein, M.; Shah, N. J.; Hammers, H.; Hutson, T. E.; Chisamore, M.; Karim, D.; Mattson, P.; Lightcap, E.; Drees, J.; Harrison, B.; Holm, M.; Bose, N.; Thomas, C. T.; Motzer, R. J. |
| Abstract Title: | A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan (WELIREG(TM)) in patients with advanced or metastatic renal cell carcinoma, NCT06234605 |
| Meeting Title: | 6th Kidney Cancer Research Summit (KCRS 2024) |
| Keywords: | renal cell carcinoma; clear cell carcinoma |
| Journal Title: | The Oncologist |
| Volume: | 29 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Jul 11-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S13 |
| Language: | English |
| ACCESSION: | WOS:001289325400012 |
| DOI: | 10.1093/oncolo/oyae181.019 |
| PROVIDER: | wos |
| PMCID: | PMC11301875 |
| Notes: | Meeting Abstract: 5 -- Abstract citation ID: oyae181.019 -- Meeting also took place virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
